Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression
- Autor
- DIELEMAN, Jeanne P1 2 3 ; STURKENBOOM, Miriam C. J. M1 2 3 ; WIT, Ferdinand W4 ; JAMBROES, Marielle4 ; MULDER, Jan-Willem5 ; TEN VEEN, Jacob H6 ; JUTTMANN, Job7 ; STRICKER, Bruno H. C1 2 3 8 ; LANGE, Joep M. A4 ; VAN DER ENDE, Marchina E3
[1] Pharmaco-Epidemiology Unit, Erasmus University Medical Centre, Rotterdam, Netherlands
[2] Department of Epidemiologyand Biostatistics, Erasmus University Medical Centre, Rotterdam, Netherlands
[3] Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands
[4] National AIDS Therapy Evaluation Centre, Academic Medical Centre, Amsterdam, Netherlands
[5] Department of Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands
[6] Department of Internal Medicine II, Prinsengracht, Amsterdam, Netherlands
[7] Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, Netherlands
[8] Dutch Inspectorate for Health Care, The Hague, Netherlands
ATHENA (AIDS Therapy Evaluation, The Netherlands) Study Group, Netherlands - Fuente
The Journal of infectious diseases. 2002, Vol 185, Num 9, pp 1261-1268 ; ref : 28 ref
- CODEN
- JIDIAQ
- ISSN
- 0022-1899
- Campo Científico
- Immunology, immunopathology, allergology; Microbiology, infectious diseases; Tropical medicine
- Editor
- University of Chicago Press, Chicago, IL
- País de la publicación
- United States
- Tipo de documento
- Article
- Idioma
- English
- Palabra clave (fr)
- Antiviral Commutation Composé non nucléoside Etude comparative Facteur risque Homme Immunodéficit Inhibiteur enzyme Inhibiteur protease Inhibiteur reverse transcriptase Névirapine Peptidases RNA-directed DNA polymerase SIDA Suppression Traitement Virus HIV1 Virus immunodéficience humaine Pays Bas Enzyme Hydrolases Immunopathologie Infection Lentivirus Nucleotidyltransferases Retroviridae Transferases Virose Virus Europe
- Palabra clave (in)
- Antiviral Switching Non nucleoside compound Comparative study Risk factor Human Immune deficiency Enzyme inhibitor Protease inhibitor Reverse transcriptase inhibitor Nevirapine Peptidases RNA-directed DNA polymerase AIDS Suppression Treatment HIV-1 virus Human immunodeficiency virus Netherlands Enzyme Hydrolases Immunopathology Infection Lentivirus Nucleotidyltransferases Retroviridae Transferases Viral disease Virus Europe
- Palabra clave (es)
- Antiviral Conmutación Compuesto no nucleósido Estudio comparativo Factor riesgo Hombre Inmunodeficiencia Inhibidor enzima Inhibidor proteasa Inhibitor reverse transcriptase Nevirapina Peptidases RNA-directed DNA polymerase SIDA Supresión Tratamiento HIV-1 virus Human immunodeficiency virus Holanda Enzima Hydrolases Inmunopatología Infección Lentivirus Nucleotidyltransferases Retroviridae Transferases Virosis Virus Europa
- Clasificación
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Disciplina
- Infectious pathology Pharmacological treatments
- Procedencia
- Inist-CNRS
- Base de datos
- PASCAL
- Identificador INIST
- 14158243
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Acceso al documento
Install on your browser
DOI
10.1086/340131 
https://dx.doi.org/10.1086/340131
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"185\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1261\";s:8:\"\u0000*\u0000epage\";s:4:\"1268\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"DIELEMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeanne P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:27:\"STURKENBOOM, Miriam C. J. M\";i:1;s:16:\"WIT, Ferdinand W\";i:2;s:18:\"JAMBROES, Marielle\";i:3;s:18:\"MULDER, Jan-Willem\";i:4;s:17:\"TEN VEEN, Jacob H\";i:5;s:13:\"JUTTMANN, Job\";i:6;s:20:\"STRICKER, Bruno H. C\";i:7;s:16:\"LANGE, Joep M. A\";i:8;s:24:\"VAN DER ENDE, Marchina E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Panist
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"185\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1261\";s:8:\"\u0000*\u0000epage\";s:4:\"1268\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"DIELEMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeanne P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:27:\"STURKENBOOM, Miriam C. J. M\";i:1;s:16:\"WIT, Ferdinand W\";i:2;s:18:\"JAMBROES, Marielle\";i:3;s:18:\"MULDER, Jan-Willem\";i:4;s:17:\"TEN VEEN, Jacob H\";i:5;s:13:\"JUTTMANN, Job\";i:6;s:20:\"STRICKER, Bruno H. C\";i:7;s:16:\"LANGE, Joep M. A\";i:8;s:24:\"VAN DER ENDE, Marchina E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Istex
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Acceso mediante Unpaywall
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"185\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1261\";s:8:\"\u0000*\u0000epage\";s:4:\"1268\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"DIELEMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeanne P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:27:\"STURKENBOOM, Miriam C. J. M\";i:1;s:16:\"WIT, Ferdinand W\";i:2;s:18:\"JAMBROES, Marielle\";i:3;s:18:\"MULDER, Jan-Willem\";i:4;s:17:\"TEN VEEN, Jacob H\";i:5;s:13:\"JUTTMANN, Job\";i:6;s:20:\"STRICKER, Bruno H. C\";i:7;s:16:\"LANGE, Joep M. A\";i:8;s:24:\"VAN DER ENDE, Marchina E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Europe PubMed Central
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"185\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1261\";s:8:\"\u0000*\u0000epage\";s:4:\"1268\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"DIELEMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeanne P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:27:\"STURKENBOOM, Miriam C. J. M\";i:1;s:16:\"WIT, Ferdinand W\";i:2;s:18:\"JAMBROES, Marielle\";i:3;s:18:\"MULDER, Jan-Willem\";i:4;s:17:\"TEN VEEN, Jacob H\";i:5;s:13:\"JUTTMANN, Job\";i:6;s:20:\"STRICKER, Bruno H. C\";i:7;s:16:\"LANGE, Joep M. A\";i:8;s:24:\"VAN DER ENDE, Marchina E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Base Search
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/340131\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The Journal of infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"185\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1261\";s:8:\"\u0000*\u0000epage\";s:4:\"1268\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-1899\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"DIELEMAN\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeanne P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:27:\"STURKENBOOM, Miriam C. J. M\";i:1;s:16:\"WIT, Ferdinand W\";i:2;s:18:\"JAMBROES, Marielle\";i:3;s:18:\"MULDER, Jan-Willem\";i:4;s:17:\"TEN VEEN, Jacob H\";i:5;s:13:\"JUTTMANN, Job\";i:6;s:20:\"STRICKER, Bruno H. C\";i:7;s:16:\"LANGE, Joep M. A\";i:8;s:24:\"VAN DER ENDE, Marchina E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JIDIAQ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:162:\"Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante arXiv
